These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25374013)

  • 21. Tissue type plasminogen activator facilitates NMDA-receptor-mediated retinal apoptosis through an independent fibrinolytic cascade.
    Kumada M; Niwa M; Hara A; Matsuno H; Mori H; Ueshima S; Matsuo O; Yamamoto T; Kozawa O
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1504-7. PubMed ID: 15790922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
    Lockwood CJ; Krikun G; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activators and inhibitors of the plasminogen system in Alzheimer's disease.
    Barker R; Kehoe PG; Love S
    J Cell Mol Med; 2012 Apr; 16(4):865-76. PubMed ID: 21790972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelial cell proteases: physiological role and regulation.
    Menashi S; Lu H; Soria C; Legrand Y
    Baillieres Clin Haematol; 1993 Sep; 6(3):559-76. PubMed ID: 7517736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of serpins and their cognate proteases in muscle after crush injury.
    Festoff BW; Reddy RB; VanBecelaere M; Smirnova I; Chao J
    J Cell Physiol; 1994 Apr; 159(1):11-8. PubMed ID: 8138578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
    Perides G; Noring R; Klempner MS
    Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
    Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
    Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
    Conese M; Blasi F
    Biol Chem Hoppe Seyler; 1995 Mar; 376(3):143-55. PubMed ID: 7612191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasminogen activator inhibitor-1.
    Gils A; Declerck PJ
    Curr Med Chem; 2004 Sep; 11(17):2323-34. PubMed ID: 15379715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.
    Sazonova IY; McNamee RA; Houng AK; King SM; Hedstrom L; Reed GL
    J Thromb Haemost; 2009 Aug; 7(8):1321-8. PubMed ID: 19566545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for an active fibrinolytic system in normal human bone marrow.
    McWilliam NA; Robbie LA; Barelle CJ; Adey G; Prasad S; Bennett B; Booth NA
    Br J Haematol; 1996 Apr; 93(1):170-6. PubMed ID: 8611456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1.
    Dewerchin M; Collen D; Lijnen HR
    Thromb Haemost; 2001 Aug; 86(2):640-6. PubMed ID: 11522016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
    Idell S
    Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
    Dai E; Viswanathan K; Sun YM; Li X; Liu LY; Togonu-Bickersteth B; Richardson J; Macaulay C; Nash P; Turner P; Nazarian SH; Moyer R; McFadden G; Lucas AR
    J Biol Chem; 2006 Mar; 281(12):8041-50. PubMed ID: 16407226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.